ERRATA

The December 20, 2013, original report by Yothers et al, entitled “Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin” (J Clin Oncol 31:4512-4519, 2013), contained an error.

In Table 2, the stages (by nodal status) “II v IIIC” and “IIIA/B v IIIC” were given incorrectly. Corrected Table 2 is reprinted below in its entirety.

The authors apologize for the mistake.

DOI: 10.1200/JCO.2014.55.6282; published March 10, 2014

Table 2. Multivariable Analysis: Relationship of Clinical and Pathologic Covariates with Risk of Recurrence in NSABP C-07

Variable	Categories	HR	95% CI	P
Stage (by nodal status)				< .001
	III A/B v II	0.97	0.55 to 1.71	
	III C v II	2.07	1.16 to 3.68	
Treatment	5-FU+Ox v 5-FU	0.82	0.64 to 1.06	.12
MMR	MMR-D v MMR-P	0.27	0.12 to 0.62	< .001
T-stage	T4 st II & T3-T4 st III v T3 st II & T1-T2 st III	3.04	1.84 to 5.02	< .001
Nodes examined	< 12 v ≥ 12	1.51	1.17 to 1.95	.002
Tumor grade	High v Low	1.36	1.02 to 1.82	.041
Recurrence Score	Continuous per 25 units	1.57	1.19 to 2.08	.001

The January 10, 2014, article by Sivendran et al, entitled “Adverse Event Reporting in Cancer Clinical Trial Publications” (J Clin Oncol 32:83-89, 2014), contained an error.

In the Glossary Terms section, the term was listed as “Linear regression analysis” but gave the definition for “Logistic regression analysis.” The definition for “Linear regression anal-

ysis” should have been given as “The estimation of the slopes for each of the explanatory variables in a linear regression model. That is, finding the best fit line.”

Journal of Clinical Oncology apologizes for the mistake.

DOI: 10.1200/JCO.2014.56.6290; published March 10, 2014